MedPath

Endometrial Advancement After Rec or u-HCG Triggering

Phase 4
Completed
Conditions
Infertility
Interventions
Drug: 10000 IU urinary HCG
Drug: 250 mcg recombinant HCG
Registration Number
NCT00953628
Lead Sponsor
Universitair Ziekenhuis Brussel
Brief Summary

The purpose of this study is to investigate any potential advantages of replacing human chorionic gonadotropin (uhCG) with recombinant human chorionic gonadotropin (recHCG) for final oocyte maturation with regard to Ovarian hyperstimulation syndrome (OHSS)pathophysiology, endometrium receptivity and embryo quality and clinical pregnancy.

Detailed Description

Biopsies of endometrium were taken in different groups Pregnancy rates were compared among defferent groups

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
130
Inclusion Criteria
  • Less than 36 years old
  • Male or tubal infertility
  • FSH<12 on day 3
Read More
Exclusion Criteria
  • Endometriosis stage 3 & 4
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
o Group A=uHCG ovul trig10000 IU urinary HCGHCG for triggering
o Group B=recHCG ovul trig250 mcg recombinant HCGrecombinant HCG for triggering
Primary Outcome Measures
NameTimeMethod
endometrium histology on the day of OPUday of oocytre pick up
Secondary Outcome Measures
NameTimeMethod
pregnancy rate14 days after oocyte pick up

Trial Locations

Locations (1)

Centre for Reproductive Medicine, UZ Brussel

🇧🇪

Brussels, Jette, Belgium

© Copyright 2025. All Rights Reserved by MedPath